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Abstract
Introduction
The low incidence of oesophageal adenocarcinoma (EAC) in Barrett’s oesophagus (BE)
patients reinforces the need for risk stratification tools to make BE surveillance more effec-
tive. Therefore, we have undertaken a systematic review and meta-analysis of published
studies on immunohistochemical (IHC) biomarkers in BE to determine the value of IHC bio-
markers as neoplastic predictors in BE surveillance.
Materials and methods
We searched MEDLINE, EMBASE, Web of Science, CENTRAL, Pubmed publisher, and
Google scholar. All studies on IHC biomarkers in BE surveillance were included. ORs were
extracted and meta-analyses performed with a random effects model.
Results
16 different IHC biomarkers were studied in 36 studies. These studies included 425 cases
and 1835 controls. A meta- analysis was performed for p53, aspergillus oryzae lectin (AOL),
Cyclin A, Cyclin D and alpha-methylacyl-CoA racemase. Aberrant p53 expression was sig-
nificantly associated with an increased risk of neoplastic progression with an OR of 3.18
(95% CI 1.68 to 6.03). This association was confirmed for both non-dysplastic BE and BE
with low-grade dysplasia (LGD). Another promising biomarker to predict neoplastic progres-
sion was AOL, with an OR of 3.04 (95% CI 2.05 to 4.49).
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Discussion
Use of p53 IHC staining may improve risk stratification in BE surveillance. Aberrant p53
expression in BE patients appeared to be associated with a significantly increased risk of
neoplastic progression for both non-dysplastic and LGD BE patients.
Introduction
Development of oesophageal adenocarcinoma (EAC) is related to Barrett’s oesophagus (BE), a
premalignant condition of the distal oesophagus. In BE, the pre-existent squamous epithelium
is replaced by columnar epithelium which develops under the influence of chronic acid and
bile reflux and frequently contains goblet cells [1–3]. The progression from BE to EAC is a
gradual process, in which intestinal metaplasia (IM) evolves to low-grade dysplasia (LGD),
high-grade dysplasia (HGD) and eventually EAC [4]. Therefore, current guidelines recom-
mend endoscopic surveillance in BE patients to detect HGD or EAC at an early stage, with the
aim to improve survival rates [5, 6]. Several studies have shown that patients diagnosed with
EAC during BE surveillance have earlier staged tumors and probably better survival compared
to those diagnosed after the onset of symptoms [7–10].
The estimated incidence of EAC in patients with BE was reported to be between 0.5 and 1%
per year [11–14]. However, more recent population-based studies and two meta-analyses have
set this risk around 0.12% to 0.38% per year [15–18]. This relatively low annual risk reinforces
the need for risk stratification tools to make BE surveillance more effective. BE length, male
gender, smoking, and LGD are known risk factors for progression to HGD and EAC [13, 15,
18–20]. Two large population studies confirmed that patients with LGD have an approxi-
mately five times higher risk of progression compared to patients with non-dysplastic BE [15,
18]. Thus, more intensive surveillance is recommended in BE patients with LGD [5, 6]. How-
ever, the histological diagnosis of LGD is subject to a considerable inter- and intra-observer
variation, because of sample error and overlap with features of non-neoplastic regenerative
changes [21–24].
Because none of the current clinical and histologic criteria are able to accurately predict
which patients are likely to progress to HGD or EAC, there is an increasing interest in (molec-
ular) biomarkers. Many immunohistochemical (IHC) biomarkers have been studied in BE
progression, mainly because they can be applied to standard histological samples. In clinical
practice, IHC biomarkers are relatively easily applicable compared to other techniques. Cur-
rently, the addition of p53 IHC to the histological assessment is recommended in the guideline
of the British Society of Gastroenterology as it may improve the diagnostic reproducibility of a
histological diagnosis of LGD [5]. The use of IHC biomarkers as independent predictor of neo-
plastic progression is not yet performed in routine clinical care, neither for p53, nor for other
IHC biomarkers. Therefore, this study aims to provide a systematic review and meta-analyses
of all retrospective case control or cohort studies and prospective cohort studies investigating
IHC biomarkers as predictor of neoplastic progression in patients with BE.
Materials and methods
This review was conducted according to the PRISMA and MOOSE guidelines (S1 MOOSE
checklist, S1 PRISMA checklist) [25, 26].
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Definitions
BE was defined as columnar lined oesophagus (CLE). Neoplastic progression was defined as
the development of HGD or EAC during follow up. Patients with neoplastic progression were
classified as cases and patients without neoplastic progression as controls.
Data sources and searches
Records were identified by searching the following electronic databases: 1. EMBASE, 2. MED-
LINE, 3. Web of Science, 4. CENTRAL, 5. PubMed Publisher, 6. Google scholar until 09-12-
2016 (S1 Search). The search strategy was constructed by applying a sensitivity maximizing
approach. A combination of MESH subject headings and text words were used related to IHC
markers for progression in patients with BE. The search was confined to English language pub-
lications. Conference abstracts indexed in Embase from the years 2014–2016 were included in
order to be able to include new and unpublished papers.
Study selection
Search results were combined and duplicates removed. Every article was screened on title and
abstract level for relevance by a single author (SvO or VJ). Articles were reviewed full text by
the same two independent authors and included if they met the following criteria: (1) associa-
tion between IHC biomarker expression on formalin fixed paraffin embedded material and
risk of neoplastic progression was assessed; (2) a cohort or case-control study design; (3)
patients with known or newly diagnosed BE with or without LGD at baseline; (4) patients
defined as cases had to have progressed to either HGD or EAC during follow-up; (5) mean fol-
low-up of at least one year from the time of initial BE diagnosis; (6) the possibility to extract an
OR. Studies were excluded if: (1) BE cohorts included patients with HGD at baseline; (2) endo-
scopic therapies affecting neoplastic progression were performed during follow-up (Fig 1).
Some manuscripts studied different biomarkers within the same population, these were con-
sidered as individual studies on the level of the individual biomarker.
Data extraction
For each included study two independent authors extracted data according to a standardized
data extraction form and assessed the quality of the eligible studies (S1 Standardized data
extraction form). In case of disagreement consensus was reached by consulting a third author
(MS). Odds ratio’s (OR)s and 95% confidence intervals (CI)s of individual IHC biomarkers
were extracted or estimated from the data. If ORs could not be extracted directly from the text
or the tables, ORs were calculated indirectly by using the numbers of cases and controls with
an aberrant versus a normal IHC biomarker expression from text, tables, or figures.
Quality assessment
The quality aspects defined were: a difference at baseline between cases and controls of at least
10% (concerning baseline histology, age, sex, length of BE segment, and follow–up time),
adjustments in the form of regression for differences of known predictors of progression (such
as baseline histology, age, sex, and length of BE segment), exclusion of prevalent cases, control
stainings, number of pathologists, pathologist agreement and pathologist blinding. These
aspects were assessed and reported on but not used as exclusion criteria.
Immunohistochemical biomarkers in Barrett’s oesophagus, systematic review and meta-analysis
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Fig 1. Flow chart of the study.
https://doi.org/10.1371/journal.pone.0186305.g001
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Data synthesis and analyses
Meta-analysis were performed if at least two studies were available [27]. If multiple studies in a
single analysis included the same patients, the oldest study was excluded. An inverse variance
random-effect model was used. If data on multiple definitions of aberrant staining were avail-
able, definitions were chosen to resemble those from other included studies for that IHC bio-
marker. If only one study was available, definitions of the authors of that study were used.
Pooled estimates of effect, in the form of ORs, were calculated and investigated for statistical
heterogeneity by visual inspection and the I-squared test (I2) = [(Q-df)/Q]100%, where Q was
the chi squared statistic and df was its degree of freedom. Where possible, ORs adjusted for
most factors were used in the analysis and unadjusted and adjusted ORs were pooled if neces-
sary. Small study effects such as publication bias were assessed using a funnel plot.
Sensitivity and subgroup analyses
Sensitivity analyses were performed in case of a large standard error (if small study effects were
likely present as observed in the funnel plot), if no adjustments were made for known predic-
tors of progression (such as sex, age, histology, i.e. non-dysplastic or LGD, and BE-length),
and if only an abstract was available. We excluded individual studies from the most reliable
analysis to evaluate the impact of single studies on pooled risk estimates and heterogeneity.
Additional analyses were performed to assess if an IHC biomarker can be used as a predictor
of neoplastic progression, independent of the presence of dysplasia. Therefore, all studies were
summarized which included only non-dysplastic BE patients, only BE with LGD patients, or
in which adjustments were made for histology type. Additionally, two subgroup analyses were
performed including either non-dysplasic or LGD BE patients.
Stringency of the definition for aberrant staining used and its
interpretation
The stringency level of the definition for aberrant staining and its interpretation could lead to
variation in the predictive ability of the IHC biomarker investigated. To investigate whether
this effect might be present, the proportion of controls deemed positive was plotted against the
OR of each study.
Results
Included studies
2081 records were retrieved, after removal of duplicates. After excluding 2050 records based
on title and abstract, a total of 27 full text articles and four abstracts were assessed in detail (Fig
1). Of these, 19 full text articles and two abstracts were included in this review [28–49]. These
articles contained a total of 36 studies.
Characteristics. A total of 36 studies were included, containing 2260 patients of which
425 cases, selected from a populations of more than 7.000 BE patients. The proportion of male
patients ranged from 66% to 100%. Mean duration of follow-up varied from 11.3 months to
120 months. Most studies were retrospective case-control studies (n = 33), and three prospec-
tive cohort studies. One study defined BE as CLE without IM, other studies defined BE as CLE
with IM (n = 23), or gave no definition (n = 12). Endpoint was EAC in six studies and either
HGD or EAC in 30 studies. (Table 1).
Dilutions and definitions for aberrant staining used. For p53, the antibody DO-7
(Dako, Glostrup, Denmark) was frequently used with a dilution ranging from 1:20 to 1:1000.
The definition for aberrant IHC staining was heterogeneous. Very intense staining was
Immunohistochemical biomarkers in Barrett’s oesophagus, systematic review and meta-analysis
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Table 1. Characteristics of included studies.
Study Marker Design Patients Baseline End-point DEF
BE
Antibody
Younes et al. 1997 p53 Retrospective case-control 25 LGD/IND HGD/EAC BE, IM
+
BP-53-12 Bio Genex (m), (not
mentioned)
Gimenez 1999 p53 Retrospective case-control 6 LGD HGD/EAC NA Do-7, Dako, (m)(1:50)
Bani-Hani et al. 2000 p53 Retrospective nested
case-control
52 IM, non-HGD EAC BE, IM
+
DO-7-p53, Novocastra (m)(1:100)
Weston et al. 2001 p53 Prospective cohort 48 LGD HGD/EAC NA Zymed, (m) (not mentioned)
Skacel et al. 2002 p53 Retrospective case-control 16 LGD HGD/EAC NA Do-7, Dako, (m)(not mentioned)
Murray et al. 2006 a p53 Retrospective nested
case-control
197 IM HGD/EAC BE, IM
+
DO-7-p53, Novocastra (m)(1:100)
Brown 2008 p53 Prospective cohort 276 IM, LGD HGD/EAC NA not mentioned
Sikkema et al. 2009
a
p53 Retrospective nested
case-control
42 IM, LGD HGD/EAC BE, IM
+
Do-7, Dako, (m)(1:1000)
Bird-Lieberman
et al.2012 a
p53 Retrospective nested
case-control
356 IM,LGD HGD/EAC BE, IM
+
DO7, Leica, (1:50)
Kastelein et al. 2012
a
p53 Case-control in
prospective cohort
635 IM, LGD HGD/EAC BE, IM
+
Do-7, Dako, (m)(1:25)
Wolf et al. 2014 p53 Retrospective nested
case-control
279 IM, IND, LGD EAC NA not mentioned
Davelaar et al. 2015 p53 Prospective cohort 91 IM, IND, LGD HGD/EAC BE, IM
+
mix of DO-7 and PB53-12, Fisher
scientific, (N/A)
Horvath et al. 2016 p53 Retrospective case-control 79 IND HGD/EAC NA Do-7, Dako, (m)(1:20)
Bird-Lieberman
et al.2012 c
AOL Retrospective nested
case-control
321 IM, LGD HGD/EAC BE, IM
+
AOL 5ug biotinylated lectin, Tokyo
chem. Indust.
Wolf et al. 2014 AOL Retrospective nested
case-control
252 IM, IND, LGD EAC NA not mentioned
Pierre Lao-Sirieix
et al. 2007
Cyclin A Retrospective nested
case-control
48 IM EAC/HGD BE, IM
+
cyclin A, Novocastra (m)(1:20)
Bird-Lieberman
et al.2012 b
Cyclin A Retrospective nested
case-control
323 IM, LGD HGD/EAC BE, IM
+
Leica (m)(1:50)
Wolf et al. 2014 Cyclin A Retrospective nested
case-control
279 IM, IND, LGD EAC NA not mentioned
Van Olphen et al.
2016
Cyclin A Case-control in a
prospective cohort
625 IM, LGD HGD/EAC BE, IM
+
Leica (m)(1:200)
Bani-Hani et al. 2000 Cyclin D Retrospective nested
case-control
61 IM EAC BE, IM
+
NCL-CYCLIN D1, Novocastra (m)
(1:30)
Murray et al. 2006 b Cyclin D Retrospective nested
case-control
197 IM HGD/EAC BE, IM
+
NCL-L-CYCLIND1-GM, Novocastra,
(m)(1:50)
Horvath et al. 2016 Cyclin D Retrospective case-control 79 IND HGD/EAC NA SP4, ThermoLabVision (m)(1:100)
Kastelein et al.2013
b
AMACR Case-control in
prospective cohort
631 IM, LGD HGD/EAC BE, IM
+
clone 13H4, Thermo Scientific (m)
(1:200)
Horvath et al. 2016 AMACR Retrospective case-control 81 IND HGD/EAC NA 13H4, Zeta Corp (m)(1:100)
Lastraioli et al. 2006 hERG1 Retrospective cohort 23 IM EAC BE, IM
+
hERG1 alexis corporation (p)(1:200)
Lastraioli et al. 2016 hERG1 Case-control 94 IM EAC NA hERG1, Dival Toscana Srl (m)(1:200)
Sirieix et al. 2003 MCM2 Retrospective nested
case-control
27 IM HGD/EAC BE, IM
+
Hutchison, Cambridge, (m)(1:10)
Capello et al. 2005 CD1a Retrospective case-control 166 CLE, IM
negative
Dysplasia /
EAC
BE,
IM-
dako clone O10, (m)(1:50)
Murray et al. 2006 d β-catenin Retrospective nested
case-control
194 IM HGD/EAC BE, IM
+
G10153, Transduction Laboratories,
(m)(1:100)
Murray et al. 2006 c COX-2 Retrospective nested
case-control
196 IM HGD/EAC BE, IM
+
160112, Cayman Chemicals, (m)
(1:250)
(Continued )
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considered aberrant by all studies (being independent of the concentration used). However,
intensity of staining was not a prerequisite for considering a staining pattern aberrant in seven
studies[29–33, 37, 47]. Three more recent studies also considered a total absence of staining as
aberrant [35, 36, 39]. For aspergillus oryzae lectin (AOL), one study calculated the OR for aber-
rant AOL IHC staining in 2 or 3 epithelial compartments versus 0 or 1 compartment [34].
Another study reported multiple ORs for aberrant AOL in 1, 2, or 3 versus 0 epithelial com-
partments [39]. The OR of aberrant AOL IHC staining in 2 or 3 versus 0 or 1 compartments
was extracted from this second study and analyzed together with the data from the first study
for the meta-analysis.
Quality of studies
In 14 of the 36 studies there was at least a 10% difference in baseline histology between cases
and controls. In these studies, around 32% of the cases had IND or LGD at baseline, versus 9%
in the controls. In five studies an age difference at baseline of at least 5 years was found
between cases and controls, in four of these studies the case group was older. In six studies at
least 10% more males were included in the case groups, 96% males on average in the cases, ver-
sus 73% in controls. Information on length of the BE segment for both cases and controls was
provided in 13 studies. In cases a longer BE segment was present; on average 5.9 cm versus 4.8
cm in the controls. In 17 studies the total follow-up time differed by at least 10% between case
and control groups. On average, follow up time was 51 months versus 59 months for cases ver-
sus controls, respectively. Seven studies excluded possible prevalent cases [29, 32, 34, 47, 49].
Fourteen studies adjusted for known predictors of progression (S1 Table). 16 studies did not
describe technical validation of the staining. IHC staining was scored by one observer in 15
studies, by two observers in 13 studies, and by three observers in three studies. Kappa values
were mentioned in only eight studies. Whether slides were assessed in a blinded manner was
not mentioned in six studies, all other studies reported the use of blinding (S1 Table).
Meta-analyses
These were possible for p53, AOL, Cyclin A, Cyclin D, and alpha-methylacyl-CoA racemase
(AMACR), which were studied 13, 2, 4, 3, and 2 times respectively. Of the 13 studies, two
included patients from the same population, which resulted in exclusion of the older study in
analyses for which both would have been eligible [32, 34]. The most frequent reasons for
excluding articles were the absence of follow-up data and LGD being defined as neoplastic
Table 1. (Continued)
Study Marker Design Patients Baseline End-point DEF
BE
Antibody
Sikkema et al. 2009
b
Ki-67 Retrospective case-control 42 IM HGD/EAC BE, IM
+
Clone MIB-1, Dako (1:100)
Rossi et al. 2009 HER-2 Retrospective case-control 20 IM, LGD HGD, EAC NA HercepTest® kit, DAKOCytomation
Bird-Lieberman
et al.2012 e
Sialyl
Lewis
Retrospective nested
case-control
356 IM, LGD HGD/EAC BE, IM
+
BOND ready retrieval
Bird-Lieberman
et al.2012 d
WGA Retrospective nested
case-control
331 IM, LGD HGD/EAC BE, IM
+
Leica BOND-MAX
Bird-Lieberman
et al.2012 f
Lewis Retrospective nested
case-control
350 IM, LGD HGD/EAC BE, IM
+
CD15, BOND ready, retrieval H2 20
min Leica
Van Olphen et al.
2015
SOX2 Case-control in
prospective cohort
635 IM, LGD HGD/EAC BE, IM
+
AF2018, R&D Systems (p)(1:400)
https://doi.org/10.1371/journal.pone.0186305.t001
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progression and end-point of the study (Fig 1). Biomarkers studied only once were MCM2,
CD1a, β-catenin, COX2, Ki67, HER2, Sialyl Lewis, Wheat germ, Lewis, and SOX2. The same
group published two studies on hERG1, both including patients from the same population[46,
48]. Therefore, both studies were individually included without summary in a meta-analysis.
p53
A total of 12 studies were included in the meta-analysis. These contained 1905 patients, of
which 342 cases. One study gave multiple ORs for various expression levels of p53 [34]. For
this study, only the OR for intense overexpression of p53 staining was considered positive.
Individual patient data of one study were converted in order to extract an adjusted OR [35].
The overall OR for neoplastic progression was 7.04 (95% CI 3.68 to 13.46) for patients with
aberrant p53 expression (Table 2 and Fig 2). Aberrant p53 expression, detected in both non-
dysplastic BE and LGD patients, was significantly associated with the development of HGD or
EAC. Significant heterogeneity (I2 = 56%, P<0.010) was observed between the included stud-
ies, which can be considered a moderate amount of heterogeneity [50]. The 12 studies were
plotted in a funnel plot which shows that small study effects can be present (S1 Fig). In order
to reduce the influence of such effects a sensitivity analysis was performed, which excluded all
studies with a standard error above one. Based on this criterion, five studies remained, con-
taining 1413 patients and 289 cases. The overall OR for neoplastic progression was 4.15 (95%
CI 1.96 to 8.81) in patients with an aberrant p53 expression. (Table 2). The use of a more strin-
gent definition of aberrant staining may lead to loss of aberrant expression in cases, in controls,
or in both. In order to investigate this, the proportion of controls deemed aberrant was plotted
against the OR of each study (S2 Fig). Studies with a higher point estimate of the OR appeared
to have had less positive non-progressors. The same is seen if this is analyzed in individual
studies where multiple cut-offs for positivity are described[32, 34]. Using a more stringent cut
off resulted in a higher OR. Further sub sensitivity analyses were performed excluding studies
for which no adjusted ORs were available. Four studies remained, containing 1322 patients
and 278 cases. The overall OR for neoplastic progression was 3.18 (95% CI 1.68 to 6.03) in
patients with an aberrant p53 expression. (Table 2). Subsequently, individual studies were
excluded from this analysis, and finally also studies presented as abstracts. These sensitivity
analyses showed similar results with slightly lower point estimates compared to the main anal-
ysis. (Table 2). For three studies both unadjusted and adjusted ORs were available, and all
three adjusted ORs had a lower point estimate compared to the unadjusted ones, in line with
the outcome of our meta-analyses.
p53 as independent predictor of neoplastic progression. For this analysis studies that
did not adjust for histology at baseline were excluded. This led to the inclusion of six studies.
These studies contained a total of 1340 BE patients, of which 282 cases. The overall OR, for
aberrant p53 IHC on neoplastic progression, after stratification for histology, was 3.86 (95% CI
2.03 to 7.33). (Table 2).
p53 in non-dysplastic Barrett’s oesophagus. Two studies were included for this analysis.
These contained a total of 720 BE patients, of which 61 cases. Individual patient data of one
study was re-analyzed to provide an OR for non-dysplastic BE patients only [35]. The overall
OR for neoplastic progression to HGD or EAC in non-dysplastic BE patients was 6.12 (95% CI
2.99 to 12.52). (Table 2).
p53 in low-grade dysplasia Barrett. For this analysis four studies were included. These
contained a total of 182 BE patients, of which 37 cases. One study was re-analyzed to provide
an OR for the LGD subgroup only [35]. The overall OR for neoplastic progression to HGD or
EAC was 8.64 (95% CI 3.62 to 20.62). (Table 2).
Immunohistochemical biomarkers in Barrett’s oesophagus, systematic review and meta-analysis
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AOL
Two studies were included in this meta-analysis. These contained 573 BE patients, of which
204 cases. The overall OR for neoplastic progression in BE patients with an aberrant AOL
staining in 2 or 3 compartments, versus 0 or 1 compartments of the tissue was 3.04 (95% CI
2.05 to 4.49) (Table 3 and S3 Fig). Results of the two studies were consistent in their findings
(I2 = 0%, P = 0.85).
CYCLIN A
Four studies were included in this meta-analysis. These contained 1275 patients, of which 285
cases. The overall OR for neoplastic progression in BE patients with cyclin A positivity was
1.90 (95% CI 0.85 to 4.22) (Table 3 and S3 Fig). Results of the three studies were inconsistent
in their findings (I2 = 76%, P = 0.005).
CYCLIN D
Three studies were included in this meta-analysis. These contained 337 patients, of which 50
cases. The overall OR for neoplastic progression in BE patients with cyclin D positivity was
Table 2. Summary of meta-analyses of studies investigating p53 IHC as a predictor of neoplastic progression.
Analysis Studies Cases Controls OR 95% CI I2 References
p53 (main) 12 (Fig 2) 342 1563 7.04 3.68–13.46 56% [28–31, 33–39, 47]
p53 (excluded SE > 1) 5 289 1124 4.15 1.96–8.81 68% [29, 34–36, 39]
p53 (also excluded unadjusted ORs) 4 278 1044 3.18 1.68–6.03 55% [29, 34, 35, 39]
p53 (exclude individual study [29] from the above analysis) 3 267 1003 3.20 1.49–6.87 70% [34, 35, 39]
p53 (exclude individual study [34] from the above analysis) 3 200 766 3.64 1.57–8.41 64% [29, 35, 39]
p53 (exclude individual study [35] from the above analysis) 3 229 458 2.23 1.37–3.64 0% [29, 34, 39]
p53 (exclude individual study [39] from the above analysis) 3 138 905 3.78 1.65–8.68 52% [29, 34, 35]
p53 (also excluded abstracts) 3 138 905 3.78 1.65–8.68 52% [29, 34, 35]
p53 (only ORs stratified for histology) 6 282 1058 3.86 2.03–7.33 46% [30, 31, 34, 35, 37, 39]
p53 (only non-dysplastic BE) 2 61 659 6.12 2.99–12.52 0% [32, 35]
p53 (only LGD) 4 37 145 8.64 3.62–20.62 0% [30, 31, 35, 37]
https://doi.org/10.1371/journal.pone.0186305.t002
Fig 2. Forest plot of studies investigating p53 as a predictor of progression. Twelve studies were included.
https://doi.org/10.1371/journal.pone.0186305.g002
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1.01 (95% CI 0.14 to 7.03) (Table 3 and S3 Fig). Results of the two studies were inconsistent in
their findings (I2 = 80%, P = 0.007).
Alpha-methylacyl-CoA racemase
Two studies were included in this meta-analysis. These contained 712 patients, of which 53
cases. The overall OR for neoplastic progression in BE patients with alpha-methylacyl-CoA
racemase positivity was 4.07 (95% CI 0.66 to 25.12) (Table 3 and S3 Fig). Results of the two
studies were moderately consistent in their findings (I2 = 53%, P = 0.14).
Studies on other IHC biomarkers
The following IHC biomarkers were investigated only once: β-catenin, CD1a, COX2, HER2,
Ki67, Lewis, Mcm2, Sialyl Lewis, SOX2, and WGA. The same group published two studies on
hERG1, both including patients from the same population[46, 48]. Therefore, both studies
were individually included without summary in a meta-analysis. In the CD1a study CLE with-
out IM was used as baseline histology [45]. When considering study size and point estimate,
CD1a, SOX2, and hERG1 appeared most promising. (S4 Fig).
Discussion
This is the first systematic review and meta-analysis to assess if IHC biomarkers can be used as
an independent predictor for neoplastic progression in BE surveillance. Sixteen biomarkers
have been investigated in this setting, of which five biomarkers have been investigated more
than once. The meta-analysis showed that aberrant p53 expression was associated with a sig-
nificantly increased risk of neoplastic progression. Moreover, aberrant p53 expression pre-
dicted neoplastic progression in both non-dysplastic BE patients and BE patients with LGD.
Of the other four IHC biomarkers, AOL appeared to be most promising in predicting neoplas-
tic progression, whereas Cyclin A, Cyclin D, and alpha-methylacyl-CoA racemase are still of
limited value.
Current use of p53 IHC in BE patients differs in international guidelines. The guideline of
the British Society of Gastroenterology recommends the addition of p53 IHC staining for the
pathological assessment of BE to improve the diagnostic reproducibility of dysplasia [5]. While
the American Gastroenterological Association guideline states that: “data supporting the use
of biomarkers to confirm the histologic diagnosis of dysplasia must be considered preliminary
[51]. No guideline has yet adopted the use of IHC biomarkers to predict neoplastic progres-
sion. Two large population based studies confirmed that patients with LGD have an approxi-
mately 5 times higher risk of neoplastic progression compared to patients without LGD [15,
18]. Our meta-analysis is the first to show that BE patients, independent of the presence of
LGD, with aberrant p53 IHC have a similar increased risk to develop cancer compared to
patients with LGD. A recent publication claims to have investigated the predictive ability of
immunohistochemical biomarkers [52]. However, they reported on samples either obtained
Table 3. Summary of meta-analyses of studies investigating IHC biomarkers other than p53 as a predictor of neoplastic progression.
Analysis Studies Cases Controls OR 95% CI I2
AOL 2 (S3 Fig) 204 369 3.04 2.04–4.49 0%
Cyclin A 4 (S3 Fig) 285 990 1.90 0.85–4.22 76%
Cyclin D 3 (S3 Fig) 50 287 1.01 0.14–7.03 80%
AMACR 2 (S3 Fig) 53 659 4.07 0.66–25.12 53%
https://doi.org/10.1371/journal.pone.0186305.t003
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from a resection specimen or from cases and controls without follow-up. Therefore, based on
their current dataset, their current conclusion, i.e. that p53 overexpression predicts malignant
progression, is not justified [53].
Although routine p53 IHC will incur higher cost than histological assessment alone, appli-
cation of this marker has the potential to reduce the overall costs related to BE surveillance by
improved risk stratification using expression of p53 IHC in combination with other predictors
of progression, such as histology, sex, age, and length of the BE segment. Better risk stratifica-
tion could result in both earlier detection of lesions in patients at risk, and a reduction in endo-
scopic and pathology recources for patients that will never develop progression. The disparity
in ORs of neoplastic progression found in the various studies may be explained by differences
in staining methods, including antibodies used, antigen retrieval methods, definitions, and
interpretations of aberrant staining used. Therefore, special consideration should be given to
the protocol of staining and the definition and interpretation used for aberrant expression.
Some studies did not consider loss of p53 staining aberrant, which might have contributed to
the protocol being less predictive compared to other studies. By using a more stringent defini-
tion of aberrant expression, cases appeared to remain p53 aberrant, while controls were not
considered aberrant (S2 Fig). Therefore, the use of more stringent definitions and interpreta-
tions for aberrant staining appears to lead to a higher predictive ability of p53 IHC.
The strength of this paper is the focus on IHC biomarkers as a relatively easy applicable tool
to improve risk stratification in BE surveillance. Additionally, we performed a broad search,
and the extraction of ORs from text, tables and figures resulted in the inclusion of quite a large
number of studies. The inclusion of abstracts results in an up to date overview of this field.
Because meta-analysis is the synthesis technique that is most transparent and most likely valid
also with small amount of studies included, some of the meta-analysis were performed with
only two studies, as no more studies were available. [27] This study also has its limitations,
such as the confinement to English language publications, the apparent presence of publication
bias, differences in baseline comparability within studies, and the various adjustments made
for these baseline differences. Therefore, we performed sensitivity analyses of the p53 meta-
analyses, these show that the point estimate of the OR decreased from 7.04 to 3.18 when we
accounted for these limitations. Because aberrant p53 IHC co-occurs with LGD, separate anal-
yses were performed in which we stratified for dysplastic and non-dysplastic patients. These
analyses show that aberrant p53 expression is an independent prognostic factor for neoplastic
progression.
In conclusion, we show that sixteen IHC biomarkers in BE surveillance have been studied.
Aberrant p53 expression is the most studied IHC biomarker and associated with a significantly
increased risk to develop HGD or EAC, this association was independent of the presence of
LGD. Consensus amongst pathologists concerning the appropriate staining method, defini-
tion, and interpretation of aberrant p53 expression is currently low, and more consensus is
required. Other promising biomarkers such as AOL need further investigation.
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S1 Fig. Funnel plot of all studies investigating p53 IHC as a predictor of progression. The
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S2 Fig. Stringency of the definition and interpretation of aberrant p53 IHC. A more strin-
gent definition of aberrant staining, and interpretation of that definition, may lead to loss of
aberrant expression in cases, in controls, or in both. In order to investigate this, the proportion
of controls deemed aberrant was plotted against the OR of each study with a standard error
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below 1. The use of a more stringent definition and interpretation for aberrant p53 staining
appeared to result in a bigger reduction in the number of controls considered to have aberrant
staining, compared to cases. Thus, by applying a more stringent definition and interpretation,
the predictive value of p53 for neoplastic progression appears to increase. Formal statistical
tests were not performed due to the limited number of data points and the post hoc nature of
this analysis.
(EPS)
S3 Fig. Forest plot of all studies investigating AOL, Cyclin A, Cyclin D, and AMACR as a
predictor of progression. (A) Two studies were included in the forest plot for AOL. (B) Four
studies were included in the forest plot for Cyclin A. (C) Three studies were included in the
forest plot for Cyclin D. (D) Two studies were included in the forest plot for AMACR.
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S4 Fig. Forest plot, without meta-analysis, of all studies investigating IHC biomarkers
which have been studied only once. 12 studies were included in this forest plot.
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